Loading...
Market
Will Medicare and Medicaid cover anti-obesity drugs like Wegovy by end of 2025?
3
Biden•Medicare•Medicaid•Wegovy•Ozempic•Zepbound•Americans•Congress•Gwen Moore•Raul Ruiz•Novo Nordisk•Eli Lilly
Resolution / Starting Odds
Yes • 50%
No • 50%
Official announcements from the Centers for Medicare & Medicaid Services (CMS) or relevant government publications
Story
Biden Proposes Medicare, Medicaid Cover Obesity Drugs Like Wegovy for Over 7 Million Americans
Nov 26, 2024, 02:41 PM
The Biden administration has proposed expanding Medicare and Medicaid coverage to include anti-obesity medications, such as Wegovy, Ozempic, and Zepbound. This initiative aims to recognize obesity as a treatable disease and would potentially make these medications accessible to 3.4 million Americans with Medicare and 4 million Americans with Medicaid who are living with obesity. The proposed expansion could reduce out-of-pocket expenses for some individuals by up to 95% and is estimated to cost taxpayers approximately $35 billion over the next nine years. The plan has garnered support from bipartisan members of Congress, including Representatives Gwen Moore and Raul Ruiz, and is seen as a significant step toward addressing obesity as a public health issue. Following the announcement, shares of weight-loss drug makers Novo Nordisk and Eli Lilly rose.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Approved as proposed • 25%
Approved with modifications • 25%
Rejected • 25%
No decision by deadline • 25%
Less than $30 billion • 25%
$30 billion to $35 billion • 25%
$35 billion to $40 billion • 25%
More than $40 billion • 25%
Cost concerns • 25%
Public health benefits • 25%
Lobbying influence • 25%
Other • 25%
Less than 5 million • 25%
5 to 7 million • 25%
7 to 9 million • 25%
More than 9 million • 25%